DIETOTHERAPY AS A PRIORITY TREATMENT POLICY FOR PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE
Issue:
7
Year:
2017
The paper analyzes the role of dietotherapy in the treatment of patients with non-alcoholic fatty liver disease (NAFLD). According to current clinical guidelines, dietotherapy and lifestyle changes are the basic treatment policy for patients with NAFLD regardless of its clinical form. A 7-10% weight loss is an obligatory condition for a clinically significant regression of necroinflammatory changes in the liver. The best effect of therapy for NAFLD is achieved through a low-calorie diet in combination with exercises.
Keywords:
therapy
hepatology
nonalcoholic fatty liver disease
nonalcoholic steatohepatitis
liver fibrosis
dietotherapy
diet
treatment
psyllium
References:
- Torres D., Harrison S. Nonalcoholic Fatty Liver Disease. In.: Sleisenger and Fordtran's Gastrointestinal and Liver Disease: Pathophysiology, Diagnosis, Management. Edited by M. Feldman, L. Friedman, L. Brandt. 10th ed. 2015.
- Maev I.V., Andreev D.N., Dicheva D.T. i dr. Nealkogol'naja zhirovaja bolezn' pecheni: posobie dlja vrachej / M.: PrimaPrint, 2017.
- Younossi Z., Koenig A., Abdelatif D. et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes // Hepatology. – 2016; 64 (1): 73–84.
- Maev I.V., Kucherjavyj Ju.A., Andreev D.N. Ozhirenie i komorbidnost': posobie dlja vrachej / M.: PrimaPrint, 2016.
- Bellentani S., Saccoccio G., Masutti F. et al. Prevalence of and risk factors for hepatic steatosis in Northern Italy // Ann. Intern. Med. – 2000; 132 (2): 112–7.
- Dam-Larsen S., Franzmann M., Andersen I. et al. Long term prognosis of fatty liver: risk of chronic liver disease and death // Gut. – 2004; 53: 750–5.
- Dyson J., Anstee Q., McPherson S. Non-alcoholic fatty liver disease: a practical approach to diagnosis and staging // Frontline Gastroenterol. – 2014; 5 (3): 211–8.
- Maev I.V., Andreev D.N. Nealkogol'naja zhirovaja bolezn' pecheni: mehanizmy razvitija, klinicheskie formy i medikamentoznaja korrektsija // Consilium Medicum (Pril. Gastroenterologija). – 2012; 2: 36–9.
- Wong V., Wong G., Choi P. et al. Disease progression of non-alcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years // Gut. – 2010; 59: 969–74.
- Le M., Devaki P., Ha N. et al. Prevalence of non-alcoholic fatty liver disease and risk factors for advanced fibrosis and mortality in the United States // PLoS One. – 2017; 12 (3): e0173499.
- Maev I.V., Kuznetsova E.I., Andreev D.N. i dr. Sovremennye i perspektivnye podhody k diagnostike nealkogol'noj zhirovoj bolezni pecheni // Consilium Medicum. – 2015; 8: 20–7.
- Andreev D.N., Dicheva D.T., Kuznetsova E.I. i dr. Nealkogol'naja zhirovaja bolezn' pecheni: lechenie s pozitsij dokazatel'noj meditsiny // Lechaschij vrach. – 2017; 2: 12–8.
- European Association for the Study of the Liver (EASL). European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease // J. Hepatol. – 2016; 64 (6): 1388–402.
- Ivashkin V.T., Maevskaja M.V., Pavlov Ch.S. i dr. Klinicheskie rekomendatsii po diagnostike i lecheniju nealkogol'noj zhirovoj bolezni pecheni Rossijskogo obschestva po izucheniju pecheni i Rossijskoj gastroenterologicheskoj assotsiatsii // Ros. zhurn. gastroenterol., gepatol., koloproktol. – 2016; 2: 24–42.
- Maev I.V., Gegel' N.V., Dicheva D.T. i dr. Rasstrojstva pischevogo povedenija v svete klinicheskih rekomendatsij po diagnostike i lecheniju nealkogol'noj zhirovoj bolezni pecheni // Consilium Medicum. – 2016; 8: 59–63.
- Harrison S., Fecht W., Brunt E. et al. Orlistat for overweight subjects with nonalcoholic steatohepatitis: a randomized, prospective trial // Hepatology. – 2009; 49: 80–6.
- Promrat K., Kleiner D., Niemeier H. et al. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis // Hepatology. – 2010; 51: 121–9.
- Vilar-Gomez E., Martinez-Perez Y., Calzadilla-Bertot L. et al. Weight loss via lifestyle modification significantly reduces features of nonalcoholic steatohepatitis // Gastroenterology. – 2015; 149: 367–78.
- Musso G., Cassader M., Rosina F. et al. Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials // Diabetologia. – 2012; 55: 885–904.
- Glass L., Dickson R., Anderson J. et al. Total body weight loss of 10% is associated with improved hepatic fibrosis in patients with nonalcoholic steatohepatitis // Dig. Dis. Sci. – 2015; 60: 1024–30.
- Chalasani N., Younossi Z., Lavine J. et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology // Gastroenterology. – 2012; 142: 1592–609.
- Professional Practice Committee for the Standards of Medical Care in Diabetes-2016. Obesity management for the treatment oftype 2 diabetes // Diabetes Care. – 2016; 39: 47–51.
- Strychar I. Diet in the management of weight loss // CMAJ. – 2006; 174 (1): 56–63.
- Fan J., Cao H. Role of diet and nutritional management in nonalcoholic fatty liver disease // J. Gastroenterol. Hepatol. – 2013; 28: 81–7.
- Hannah W. Jr., Harrison S. Lifestyle and Dietary Interventions in the Management of Nonalcoholic Fatty Liver Disease // Dig. Dis. Sci. – 2016; 61 (5): 1365–74.
- Ouyang X., Cirillo P., Sautin Y. et al. Fructose consumption as a risk factor for nonalcoholic fatty liver disease // J. Hepatol. – 2008; 48: 993–9.
- Hsu C., Ness E., Kowdley K. Nutritional Approaches to Achieve Weight Loss in Nonalcoholic Fatty Liver Disease // Adv. Nutr. – 2017; 8 (2): 253–65.
- McGavock J., Anderson T., Lewanczuk R. Sedentary lifestyle and antecedents of cardiovascular disease in young adults // Am. J. Hypertens. – 2006; 19: 701–7.
- Zhu S., St-Onge M., Heshka S. et al. Lifestyle behaviors associated with lower risk of having the metabolic syndrome // Metab. Clin. Exp. – 2004; 53: 1503–11.
- Church T., Kuk J., Ross R. et al. Association of cardiorespiratory fitness, body mass index, and waist circumference to nonalcoholic fatty liver disease // Gastroenterology. – 2006; 130: 2023–30.
- Ismail I., Keating S., Baker M. et al. A systematic review and meta-analysis of the effect of aerobic vs. resistance exercise training on visceral fat // Obes. Rev. – 2012; 13 (1): 68–91.
- Houghton D., Thoma C., Hallsworth K. et al. Exercise Reduces Liver Lipids and Visceral Adiposity in Patients With Nonalcoholic Steatohepatitis in a Randomized Controlled Trial // Clin. Gastroenterol. Hepatol. – 2017; 15 (1): 96–102.e3.
- Hallsworth K., Fattakova G., Hollingsworth K. et al. Resistance exercise reduces liver fat and its mediators in nonalcoholic fatty liver disease independent of weight loss // Gut. – 2011; 60: 1278–83.
- Johnson N., Sachinwalla T., Walton D. et al. Aerobic exercise training reduces hepatic and visceral lipids in obese individuals without weight loss // Hepatology. – 2009; 50: 1105–12.
- Parker H., Johnson N., Burdon C. et al. Omega-3 supplementation and nonalcoholic fatty liver disease: A systematic review and meta-analysis // J. Hepatol. – 2012; 56: 944–51.
- Marik P., Varon J. Omega-3 supplements and the risk of cardiovascular events: A systematic review // Clin. Card. – 2009; 32: 365–72.
- Klatsky A., Armstrong M. Alcohol, smoking, coffee, and cirrhosis // Am. J. Epidemiol. – 1992; 136: 1248–57.
- Freedman N., Everhart J. et al. Coffee intake is associated with lower rates of liver disease progression in chronic hepatitis C // Hepatology. – 2009; 50: (5): 1360–9.
- Zelber-Sagi S., Salomone F., Webb M. et al. Coffee consumption and nonalcoholic fatty liver onset: a prospective study in the general population // Transl. Res. – 2015; 165 (3): 428–36.
- Wijarnpreecha K., Thongprayoon C., Ungprasert P. Coffee consumption and risk of nonalcoholic fatty liver disease: a systematic review and meta-analysis // Eur. J. Gastroenterol. Hepatol. – 2017; 29 (2): 8–12.
- Ginzburg M.M. Otchet «Opyt primenenija preparata Mukofal'k v kompleksnoj terapii u patsientov s ozhireniem i metabolicheskim sindromom» NII dietologii i dietoterapii / Samara, 2010.
- Komissarenko I.A., Levchenko S.V., Gudkova R.B. i dr. Effekty dlitel'nogo primenenija psilliuma pri lechenii bol'nyh s divertikuljarnoj bolezn'ju tolstoj kishki // Klin. persp. v gastroenterol., gepatol. – 2014; 3: 29–36.
- Maevskaja E.A., Maev I.V., Kucherjavyj Ju.A. i dr. Otsenka vlijanija laktulozy ili pischevyh volokon na dinamiku pokazatelej lipidnogo profilja u patsientov s funktsional'nym zaporom i nealkogol'nym steatogepatitom // Lechaschij vrach. – 2016; 4: 117–23.
- Anderson J., Allgood L., Turner J. et al. Effects of psyllium on glucose and serum lipid responses in men with type 2 diabetes and hypercholesterolemia // Am. J. Clin. Nutr. – 1999; 70 (4): 466–73.
- Gibb R., McRorie J. Jr., Russell D. et al. Psyllium fiber improves glycemic control proportional to loss of glycemic control: a meta-analysis of data in euglycemic subjects, patients at risk of type 2 diabetes mellitus, and patients being treated for type 2 diabetes mellitus // Am. J. Clin. Nutr. – 2015; 102 (6): 1604–14.
- Giacosa A., Rondanelli M. The right fiber for the right disease: an update on the psyllium seed husk and the metabolic syndrome // J. Clin. Gastroenterol. – 2010; 44 (Suppl. 1): 58–60.
- Lambeau K., McRorie J. Jr. Fiber supplements and clinically proven health benefits: How to recognize and recommend an effective fiber therapy // J. Am. Assoc. Nurse Pract. – 2017; 29 (4): 216–23.